Total Valuation
Lisata Therapeutics has a market cap or net worth of €17.87M. The enterprise value is €18.99M.
Market Cap€17.87M
Enterprise Value€18.99M
Share Statistics
Lisata Therapeutics has 9,106,391 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,106,391
Owned by Insiders10.45%
Owned by Institutions0.91%
Financial Efficiency
Lisata Therapeutics’s return on equity (ROE) is -1.12 and return on invested capital (ROIC) is -117.30%.
Return on Equity (ROE)-1.12
Return on Assets (ROA)-0.93
Return on Invested Capital (ROIC)-117.30%
Return on Capital Employed (ROCE)-1.24
Revenue Per Employee8.10K
Profits Per Employee-789.81K
Employee Count21
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lisata Therapeutics is ―. Lisata Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio95.05
PB Ratio1.09
Price to Fair Value1.09
Price to FCF-1.01
Price to Operating Cash Flow-1.41
PEG Ratio0.05
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of 170.00K and earned -16.59M in profits. Earnings per share was -1.91.
Revenue170.00K
Gross Profit24.00K
Operating Income-18.21M
Pretax Income-17.55M
Net Income-16.59M
EBITDA-17.40M
Earnings Per Share (EPS)-1.91
Cash Flow
In the last 12 months, operating cash flow was -13.63M and capital expenditures -28.00K, giving a free cash flow of -13.66M billion.
Operating Cash Flow-13.63M
Free Cash Flow-13.66M
Free Cash Flow per Share-1.50
Dividends & Yields
Lisata Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.09
52-Week Price Change38.53%
50-Day Moving Average2.87
200-Day Moving Average2.77
Relative Strength Index (RSI)55.74
Average Volume (3m)0.00
Important Dates
Lisata Therapeutics upcoming earnings date is Aug 17, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Lisata Therapeutics as a current ratio of 5.76, with Debt / Equity ratio of 0.00%
Current Ratio5.76
Quick Ratio5.76
Debt to Market Cap0.00
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lisata Therapeutics has paid -962.00K in taxes.
Income Tax-962.00K
Effective Tax Rate0.05
Enterprise Valuation
Lisata Therapeutics EV to EBITDA ratio is -0.01, with an EV/FCF ratio of -0.01.
EV to Sales1.19
EV to EBITDA-0.01
EV to Free Cash Flow-0.01
EV to Operating Cash Flow-0.01
Balance Sheet
Lisata Therapeutics has €13.06M in cash and marketable securities with €0.00 in debt, giving a net cash position of €13.06M billion.
Cash & Marketable Securities€13.06M
Total Debt€0.00
Net Cash€13.06M
Net Cash Per Share€1.43
Tangible Book Value Per Share€1.68
Margins
Gross margin is 98.82%, with operating margin of -10711.18%, and net profit margin of -9756.47%.
Gross Margin98.82%
Operating Margin-10711.18%
Pretax Margin-10322.35%
Net Profit Margin-9756.47%
EBITDA Margin-10236.47%
EBIT Margin-10322.35%
Analyst Forecast
The average price target for Lisata Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-84.25%
EPS Growth Forecast24.88%